Product
Liposome-encapsulated Daunorubicin-Cytarabine
Aliases
CPX-351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351 (4 other aliases)
21 clinical trials
26 indications
Indication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromeIndication
Myeloproliferative NeoplasmIndication
Myelodysplasia-RelatedIndication
Recurrent Acute Myeloid LeukemiaIndication
Recurrent B Acute Lymphoblastic LeukemiaIndication
Recurrent Mixed Phenotype Acute LeukemiaIndication
Recurrent T Acute Lymphoblastic LeukemiaIndication
Mixed Phenotype Acute LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
BlastsIndication
Chronic Myelomonocytic LeukemiaIndication
Therapy-Related Acute Myeloid LeukemiaIndication
Myeloid NeoplasmIndication
Persistent DiseaseIndication
Essential ThrombocythemiaIndication
MyelofibrosisIndication
Polycythemia VeraIndication
myelodysplastic syndromesClinical trial
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical TrialsStatus: Recruiting, Estimated PCD: 2029-05-15
Clinical trial
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDSStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical TrialStatus: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
A Phase I Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (AML)Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 MutationsStatus: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment TrialStatus: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory LeukemiaStatus: Withdrawn, Estimated PCD: 2023-09-01
Clinical trial
Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating AgentsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2025-01-29
Clinical trial
Phase II Study of CPX-351 in Combination With Venetoclax in Patients With Acute Myeloid Leukemia (AML)Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid NeoplasmStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)Status: Completed, Estimated PCD: 2018-12-31
Clinical trial
Open-Label Phase 2 Trial of Vyxeos in Patients With Intermediate and High-Risk Acute Myeloid Leukemia Who Have Failed an Initial Cycle of Standard Cytarabine and Daunorubicin ChemotherapyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Trial for Patients With High-Grade Myeloid Neoplasms With Measurable Residual Disease (MRD): CPX-351 vs. Immediate Allogeneic Hematopoietic Cell TransplantationStatus: Terminated, Estimated PCD: 2023-08-27
Clinical trial
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Randomized Phase 2 Study of Daunorubicin and Cytarabine Liposome + Pomalidomide Versus Daunorubicin and Cytarabine Liposome in Newly Diagnosed AML With MDS-Related ChangesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Patients With Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
CPX-351 Plus Enasidenib for Relapsed Acute Myelogenous Leukemia Characterized by the IDH2 MutationStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase Ib Trial With Dose Expansion Evaluating CPX-351 Plus Gemtuzumab Ozogamicin for Relapsed Acute Myelogenous LeukemiaStatus: Terminated, Estimated PCD: 2023-10-25
Clinical trial
Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed AML at High Risk for Induction MortalityStatus: Completed, Estimated PCD: 2020-01-22
Clinical trial
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)Status: Recruiting, Estimated PCD: 2025-12-31